Karyopharm Therapeutics (KPTI) Interest Expenses (2015 - 2025)

Karyopharm Therapeutics has reported Interest Expenses for 8 years, with the latest figure at $12.6 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 12.63% year-over-year to $12.6 million; the trailing twelve-month figure through Dec 2025 stood at $45.8 million (up 22.52% YoY), and the FY2025 full-year result was $45.8 million, up 22.52% from the prior year.
• Interest Expenses for Q4 2025 stood at $12.6 million, up from $11.0 million in the prior quarter.
• The five-year high for Interest Expenses was $12.6 million in Q4 2025, with the low at $5.0 million in Q2 2021.
• Historically, Interest Expenses has averaged $7.9 million across 5 years, with a median of $6.5 million in 2022.
• Annual changes were most pronounced in 2021 — Interest Expenses retreated 26.0% — and 2024, when it surged 87.47%.
• Karyopharm Therapeutics' Interest Expenses stood at $7.9 million in 2021, then decreased by 25.88% to $5.9 million in 2022, then advanced by 5.49% to $6.2 million in 2023, then jumped by 80.48% to $11.2 million in 2024, then climbed by 12.63% to $12.6 million in 2025.
• The last three Interest Expenses figures came in at $12.6 million (Q4 2025), $11.0 million (Q3 2025), and $11.2 million (Q2 2025), per Business Quant data.